JP2020516289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516289A5 JP2020516289A5 JP2019555834A JP2019555834A JP2020516289A5 JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5 JP 2019555834 A JP2019555834 A JP 2019555834A JP 2019555834 A JP2019555834 A JP 2019555834A JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- risk allele
- linkage disequilibrium
- subject
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028369 Alleles Proteins 0.000 claims 36
- 102100033500 Interleukin-33 Human genes 0.000 claims 35
- 108010067003 Interleukin-33 Proteins 0.000 claims 35
- 239000003814 drug Substances 0.000 claims 26
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 claims 16
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 16
- 210000003979 eosinophil Anatomy 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 12
- 210000000349 chromosome Anatomy 0.000 claims 12
- 208000006673 asthma Diseases 0.000 claims 10
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 claims 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims 6
- 201000010105 allergic rhinitis Diseases 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229950003468 dupilumab Drugs 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023121229A JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| US62/485,077 | 2017-04-13 | ||
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Division JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516289A JP2020516289A (ja) | 2020-06-11 |
| JP2020516289A5 true JP2020516289A5 (enExample) | 2021-04-22 |
| JP7321939B2 JP7321939B2 (ja) | 2023-08-07 |
Family
ID=61911717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555834A Active JP7321939B2 (ja) | 2017-04-13 | 2018-03-20 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (enExample) |
| EP (3) | EP3957752B1 (enExample) |
| JP (3) | JP7321939B2 (enExample) |
| KR (2) | KR102751957B1 (enExample) |
| CN (1) | CN110431240A (enExample) |
| AU (3) | AU2018252974B2 (enExample) |
| CA (1) | CA3059350A1 (enExample) |
| IL (2) | IL269873B2 (enExample) |
| MX (2) | MX2019012171A (enExample) |
| SG (1) | SG11201909457XA (enExample) |
| WO (1) | WO2018190990A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018252974B2 (en) * | 2017-04-13 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| MA55807A (fr) * | 2019-05-01 | 2022-03-09 | Regeneron Pharma | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33 |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| MX2024005769A (es) * | 2021-11-11 | 2024-05-24 | Regeneron Pharma | Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33). |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| FR2900817B1 (fr) * | 2006-05-12 | 2008-12-19 | Gambro Lundia Ab | Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US8367333B2 (en) * | 2008-12-12 | 2013-02-05 | Decode Genetics Ehf. | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| BR112013021473A2 (pt) | 2011-02-23 | 2020-08-04 | F. Hoffmann-La Roche Ag | anticorpos contra il33r humano e seus usos |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
| CA2894219C (en) * | 2012-12-10 | 2020-08-11 | Vib Vzw | Novel interleukin-33 inhibitors |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MX364591B (es) * | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| CA3190793A1 (en) | 2013-12-26 | 2015-07-02 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| EP3218412A1 (en) * | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| NZ736026A (en) | 2015-03-31 | 2023-02-24 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| MX2018004170A (es) * | 2015-10-06 | 2018-06-06 | Regeneron Pharma | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| AU2018252974B2 (en) * | 2017-04-13 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
-
2018
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
- 2018-03-20 KR KR1020237039438A patent/KR102751957B1/ko active Active
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en not_active Ceased
- 2018-03-20 EP EP21162316.0A patent/EP3957752B1/en active Active
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 IL IL269873A patent/IL269873B2/en unknown
- 2018-03-20 IL IL314591A patent/IL314591A/en unknown
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 EP EP25162154.6A patent/EP4549586A3/en active Pending
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active Active
- 2018-03-20 CN CN201880018649.2A patent/CN110431240A/zh active Pending
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/es unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US20230374145A1/en active Pending
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/ja active Active
-
2024
- 2024-09-13 JP JP2024158740A patent/JP2024163308A/ja active Pending
- 2024-09-30 AU AU2024220212A patent/AU2024220212A1/en active Pending
- 2024-09-30 AU AU2024220214A patent/AU2024220214A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516289A5 (enExample) | ||
| Maspero et al. | Type 2 inflammation in asthma and other airway diseases | |
| Rutgeerts et al. | A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis | |
| Atreya et al. | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease | |
| Peyrin-Biroulet et al. | Early Crohn disease: a proposed definition for use in disease-modification trials | |
| JP6563976B2 (ja) | 可溶性ヒトｓｔ−２抗体およびアッセイ法 | |
| JP2023002583A (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| Wright et al. | Cardiovascular comorbidity in rheumatic diseases a focus on heart failure | |
| JP2010516678A5 (enExample) | ||
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP2017501680A5 (enExample) | ||
| Yalcin et al. | Future perspective: biologic agents in patients with severe COVID-19 | |
| Crisan-Dabija et al. | “A chain only as strong as its weakest link”: an up-to-date literature review on the bidirectional interaction of pulmonary fibrosis and COVID-19 | |
| JP2018535394A5 (enExample) | ||
| JP2018533557A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| Gaber et al. | Clinical significance of serum interleukin-6 and− 174 G/C promoter polymorphism in Rheumatoid arthritis patients | |
| JP2017519523A (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Iskandar et al. | Ulcerative colitis: update on medical management | |
| Grainge et al. | Targeted therapeutics for severe refractory asthma: monoclonal antibodies | |
| JP2015508887A5 (enExample) | ||
| RU2015145133A (ru) | Генетические маркеры для прогнозирования восприимчивости к терапии | |
| Vande Casteele et al. | Therapeutic drug monitoring of golimumab in the treatment of ulcerative colitis | |
| David et al. | Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond |